Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy?

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 736-739

  Masci, Giovanna ^a   Magagnoli, Massimo ^a   Zucali, Paolo Andrea ^a   Castagna, Luca ^a   Carnaghi, Carlo ^a   Sarina, Barbara ^a   Pedicini, Vittorio ^a   Fallini, Monica ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; WARFARIN; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CATHETER; CATHETER THROMBOSIS; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS CATHETER; LIVER METASTASIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; THROMBOSIS PREVENTION; TREATMENT OUTCOME; CENTRAL VENOUS CATHETERIZATION; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; NEOPLASM; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; THROMBOSIS;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; CATHETERIZATION, CENTRAL VENOUS; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONAL NORMALIZED RATIO; LIVER NEOPLASMS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOSIS; WARFARIN;

EID: 0037441969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.042     Document Type: Article

References (40)

1. Lokich JJ, Becker B: Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 52:1586-1589, 1983
2. Sletnes KE, Holte H, Halvorsen S, et al: Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman catheter in ABMT patients with malignant lymphoma. Bone Marrow Transplant 17:577-581, 1996
3. Horne MK, May DJ, Alexander HR, et al: Venographic surveillance of tunneled venous access device in adult oncology patients. Ann Surg Oncol 2:174-178, 1995
4. Gould JR, Carloss HW, Skinner WL: Groshong catheter associated subclavian venous thrombosis. Am J Med 95:419-423, 1993
5. Lyon RD, Griggs KA, Johnson AM, et al: Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J Vasc Interv Radiol 10:463-467, 1999
6. Laurenzi L, Fimiani C, Faglieri N, et al: Complications with fully implantable venous access systems in oncologic patients. Tumori 82:232-236, 1996
7. Baglin TP, Boughton BJ: Central venous thrombosis due to bolus injections of anti-leukaemic chemotherapy. Br J Haematol 63:606-607, 1986
8. Ross A, Griffith C, Anderson J: Thromboembolic complications with silicone elastomer subclavian catheters. J Parenter Enteral Nutr 6:61-63, 1982
9. Eastrige BJ, Lefor TA: Complications of indwelling venous catheter devices in cancer patients. J Clin Oncol 13:233-238, 1995
10. Monreal M, Raventos A, Lerma R, et al: Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: A prospective study. Thromb Haemost 72:548-553, 1994
11. Ratcliffe M, Broadfoot C, Davidson M, et al: Thrombosis, markers of thrombotic risk, indwelling central venous catheters and efficiently of antithrombotic prophylaxis using low-dose of warfarin. Clin Lab Haematol 21:353-357, 1999
12. Coccheri S, Palareti G, Cosmi B: Oral anticoagulant therapy: Efficacy, safety and the low-dose controversy. Haemostatis 29:150-165, 1999
13. Brown MC: An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy 45:392-395, 1999
14. Mirro J, Rao BN, Kumar R, et al: A comparison of placement techniques and complications of externalized catheters and implantable port use in children with cancer. J Pediatr Surg 25:120-127, 1990
15. Bothe A, Orr G, Bistrian BR, et al: Home hyperalimentation. Compr Ther 5:54-59, 1979
16. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
17. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
18. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 355:1041-1047, 2000
19. Lokich JJ, Bothe A, Benotti P, et al: Complications and management of implanted venous access catheters. J Clin Oncol 3:710-717, 1985
20. De Cicco M, Matovic M, Balestreri I, et al: Central venous thrombosis: An early and frequent complication in cancer patients bearing long-term silastic catheter-A prospective study. Thromb Res 86:101-113, 1997
21. Levine M, Hirsh J, Gent M, et al: Double-blind randomized trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994
22. Krauth D, Holden A, Knapic N, et al: Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 59:983-985, 1987
23. Bona RD, Hickey AD, Wallace DM: Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 78:137-140, 1997
24. Columbus Investigators: Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657-662, 1997
25. Boraks P, Seale J, Price J, et al: Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 101:483-486, 1998
26. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423-428, 1990
27. Carr KM, Rabinowitz I: Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 18:3665-3667, 2000
28. Francis CW, Marder VJ, Evarts CM, et al: Two-step warfarin therapy: Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 249:374-378, 1983
29. Chlebowski RT, Gota CH, Chan KK, et al: Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 42:4827-4830, 1982
30. Seifter EJ, Brooks BJ, Urba WJ: Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 69:244-247, 1985
31. Brown MC: Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole. Clin Pharmacol Ther 64:233, 1998
32. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74, 1997
33. Afsar A, Lee C, Riddick DS: Modulation of the expression on constitutive rat hepatic cytochrome p450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol 74:150-156, 1996
34. Wajima T, Mukhopadhyay P: Possible interactions between warfarin and 5-fluorouracil. Am J Haematol 40:238, 1992
35. Scarfe MA, Israel MK: Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 28:464-467, 1994
36. Malacarne P, Maestri A: Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities. Recenti Prog Med 87:135, 1996
37. Wehbe TW, Warth JA: A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Clin Pharmacol Ther 59:360-362, 1996
38. Brown MC: Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 17:631-633, 1997
39. Kolesar JM, Johnson CL, Freeberg BL, et al: Warfarin-5-FU interaction: A consecutive case series. Pharmacotherapy 19:1445-1449, 1999
40. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000